Veradermics reports Q4 net loss $21.8M vs $5.7M last year

Cash, cash equivalents, and marketable securities totaled $141.9 million as of December 31, 2025. “2025 was a landmark year for Veradermics (MANE), marked by significant progress in advancing Phase 3 development of VDPHL01, and our momentum has continued into 2026 with our debut as a public company following the successful completion of our IPO,” said Reid Waldman, M.D., Chief Executive Officer of Veradermics. “This year, we expect two Phase 3 readouts in men and to continue to make progress toward a planned NDA submission, while also advancing the first-ever Phase 3 trial of an oral treatment for female pattern hair loss. Backed by a strong balance sheet, we are focused on executing with urgency for the men and women who have waited far too long for new treatment options for pattern hair loss.”